文献速递核素与放射性配体治疗神经核医学

嗜铬细胞瘤与副神经节瘤的全身放射性药物治疗

Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
PubMed 文献 · J Nucl Med · 2021-01-01

本文为继续医学教育文章,讨论转移性或不可手术嗜铬细胞瘤与副神经节瘤的全身放射性药物治疗,重点介绍131I-MIBG及90Y或177Lu-DOTA生长抑素类似物。美国FDA已批准高比活度131I-MIBG用于转移性或不可手术嗜铬细胞瘤或副神经节瘤,177Lu-DOTATATE在美国和欧洲获批,NCCN指南建议其用于转移性或不可手术患者。这些药物在转移性或不可手术患者中显示出姑息治疗有效的证据。

要点

  • 高比活度131I-MIBG已获FDA批准用于转移性或不可手术嗜铬细胞瘤或副神经节瘤。
  • 177Lu-DOTATATE在美国和欧洲获批,NCCN指南建议用于转移性或不可手术患者。
  • 131I-MIBG和90Y或177Lu-DOTA生长抑素类似物在转移性或不可手术患者中显示姑息治疗有效证据。

核心结论

  • 131I-MIBG和90Y或177Lu-DOTA生长抑素类似物在转移性或不可手术嗜铬细胞瘤或副神经节瘤患者中显示出姑息治疗有效的证据。

研究设计与样本

  • 本文为继续医学教育文章,讨论嗜铬细胞瘤与副神经节瘤的131I-MIBG及90Y或177Lu-DOTA生长抑素类似物治疗。

主要发现

  • 放射性标记MIBG和生长抑素受体显像为将这些放射性药物用作诊疗一体化药物奠定了基础。
  • 131I-MIBG治疗神经内分泌肿瘤有较长历史,高比活度131I-MIBG获FDA批准后该治疗可普遍获得并重新引起关注。
  • 文献中已有90Y或177Lu-DOTA偶联生长抑素类似物用于肽受体放射性核素治疗嗜铬细胞瘤与副神经节瘤的报道。

关键数值与推荐

  • 美国FDA批准高比活度131I-MIBG用于转移性或不可手术嗜铬细胞瘤或副神经节瘤。
  • 177Lu-DOTATATE在美国和欧洲获批,NCCN指南建议其用于转移性或不可手术嗜铬细胞瘤与副神经节瘤患者。

临床怎么用

  • 对转移性或不可手术嗜铬细胞瘤或副神经节瘤,可考虑131I-MIBG或90Y/177Lu-DOTA生长抑素类似物作为姑息治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whereas benign pheochromocytomas and paragangliomas are often successfully cured by surgical resection, treatment of metastatic disease can be challenging in terms of both disease control and symptom control. Fortunately, several options are available, including chemotherapy, radiation therapy, and surgical debulking. Radiolabeled metaiodobenzylguanidine (MIBG) and somatostatin receptor imaging have laid the groundwork for use of these radiopharmaceuticals as theranostic agents. 131I-MIBG therapy of neuroendocrine tumors has a long history, and the recent approval of high-specific-activity 131I-MIBG for metastatic or inoperable pheochromocytoma or paraganglioma by the U.S. Food and Drug Administration has resulted in general availability of, and renewed interest in, this treatment. Although reports of peptide receptor radionuclide therapy of pheochromocytoma and paraganglioma with 90Y- or 177Lu-DOTA conjugated somatostatin analogs have appeared in the literature, the approval of 177Lu-DOTATATE in the United States and Europe, together with National Comprehensive Cancer Network guidelines suggesting its use in patients with metastatic or inoperable pheochromocytoma and paraganglioma, has resulted in renewed interest. These agents have shown evidence of efficacy as palliative treatments in patients with metastatic or inoperable pheochromocytoma or paraganglioma. In this continuing medical education article, we discuss the therapy of pheochromocytoma and paraganglioma with 131I-MIBG and 90Y- or 177Lu-DOTA-somatostatin analogs.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Carrasquillo JA, Chen CC, Jha A, et al. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. J Nucl Med. 2021. PMID: 34475242. doi:10.2967/jnumed.120.259697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。